news-tldr.com

The important facts, the open questions, and the sources — without the churn.

← Latest briefing

Health

Observational study finds heart implant eases chest pain in refractory angina patients

A study across UK hospitals showed a coronary sinus reducer device provided pain relief for three-quarters of patients whose symptoms persisted after standard treatments.

Updated Aug 24, 2026 · 05:18 UTC1 reports

The short version

  • An observational study of 491 UK patients found that a coronary sinus reducer implant led to a significant decrease in chest pain for 75% of patients within six months.
  • The hourglass-shaped device is inserted via keyhole surgery to redirect blood flow toward oxygen-deprived heart muscle in patients with refractory angina.
  • Refractory angina affects an estimated 300,000 people in England whose severe chest pain persists despite medications, stents, and bypass surgery.
  • Researchers and heart experts caution that additional clinical trials and NHS funding approvals are required before the experimental device can become standard practice.

Key facts

  • An observational study covering 491 patients between 2014 and 2024 across 19 hospitals in England and Scotland found that a coronary sinus reducer relieved chest pain in 75% of patients within six months.[The Guardian]
  • The hourglass-shaped implant is inserted through the neck via keyhole surgery and works by narrowing a vein behind the heart to redirect blood to oxygen-deprived areas.[The Guardian]
  • Each coronary sinus reducer device costs the NHS £11,400.[The Guardian]
  • An estimated 300,000 people in England suffer from refractory angina, a condition that resists conventional treatments including stents, medication, and bypass surgery.[The Guardian]
  • The study was co-led by Dr. Ranil de Silva and Dr. Kevin Cheng, observing 474 individuals who successfully received the implant.[The Guardian]

What remains uncertain

  • It remains uncertain when or if the device will be adopted as standard NHS care, as researchers and the British Heart Foundation note that further trials and formal NHS funding approvals are required.[The Guardian]

Sources